SFY Stock Overview
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Theriva Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$1.28 |
| 52 Week Low | US$0.34 |
| Beta | 1.47 |
| 1 Month Change | -16.67% |
| 3 Month Change | 2.78% |
| 1 Year Change | -40.32% |
| 3 Year Change | -91.40% |
| 5 Year Change | -93.21% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| SFY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.2% | -5.1% | -2.0% |
| 1Y | -40.3% | -21.1% | -0.3% |
Return vs Industry: SFY underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: SFY underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| SFY volatility | |
|---|---|
| SFY Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SFY's share price has been volatile over the past 3 months.
Volatility Over Time: SFY's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Steve Shallcross | therivabio.com |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma.
Theriva Biologics, Inc. Fundamentals Summary
| SFY fundamental statistics | |
|---|---|
| Market cap | €6.68m |
| Earnings (TTM) | -€17.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs SFY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.35m |
| Earnings | -US$18.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.6% |
How did SFY perform over the long term?
See historical performance and comparison